- Home
- CMPX vs RNAC Comparison
CMPX vs RNAC Comparison
Compare CMPX & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPX
- RNAC
- Stock Information
- Founded
- CMPX 2014
- RNAC 2007
- Country
- CMPX United States
- RNAC United States
- Employees
- CMPX 35
- RNAC N/A
- Industry
- CMPX Biotechnology: Pharmaceutical Preparations
- RNAC Biotechnology: Pharmaceutical Preparations
- Sector
- CMPX Health Care
- RNAC Health Care
- Exchange
- CMPX Nasdaq
- RNAC Nasdaq
- Market Cap
- CMPX 291.8M
- RNAC 264.7M
- IPO Year
- CMPX N/A
- RNAC 2016
- Fundamental
- Price
- CMPX $2.11
- RNAC $9.64
- Analyst Decision
- CMPX Strong Buy
- RNAC Strong Buy
- Analyst Count
- CMPX 8
- RNAC 7
- Target Price
- CMPX $13.13
- RNAC $41.00
- AVG Volume (30 Days)
- CMPX 804.2K
- RNAC 76.4K
- Earning Date
- CMPX 05-08-2025
- RNAC 05-08-2025
- Dividend Yield
- CMPX N/A
- RNAC N/A
- EPS Growth
- CMPX N/A
- RNAC N/A
- EPS
- CMPX N/A
- RNAC N/A
- Revenue
- CMPX $850,000.00
- RNAC $34,173,000.00
- Revenue This Year
- CMPX N/A
- RNAC N/A
- Revenue Next Year
- CMPX N/A
- RNAC N/A
- P/E Ratio
- CMPX N/A
- RNAC N/A
- Revenue Growth
- CMPX N/A
- RNAC 31.91
- 52 Week Low
- CMPX $0.77
- RNAC $8.46
- 52 Week High
- CMPX $4.08
- RNAC $41.87
- Technical
- Relative Strength Index (RSI)
- CMPX 57.65
- RNAC 43.07
- Support Level
- CMPX $2.06
- RNAC $8.46
- Resistance Level
- CMPX $2.23
- RNAC $10.10
- Average True Range (ATR)
- CMPX 0.12
- RNAC 0.60
- MACD
- CMPX 0.01
- RNAC 0.07
- Stochastic Oscillator
- CMPX 69.23
- RNAC 54.91
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.